Relationship of In Vitro Toxicity of Technetium-99m to Subcellular Localisation and Absorbed Dose.
auger electron therapy
dosimetry
molecular radionuclide therapy
radiobiology
sodium iodide symporter
technetium
triple-negative breast cancer cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Dec 2021
15 Dec 2021
Historique:
received:
18
11
2021
revised:
08
12
2021
accepted:
09
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
1
2
2022
Statut:
epublish
Résumé
Auger electron-emitters increasingly attract attention as potential radionuclides for molecular radionuclide therapy in oncology. The radionuclide technetium-99m is widely used for imaging; however, its potential as a therapeutic radionuclide has not yet been fully assessed. We used MDA-MB-231 breast cancer cells engineered to express the human sodium iodide symporter-green fluorescent protein fusion reporter (hNIS-GFP; MDA-MB-231.hNIS-GFP) as a model for controlled cellular radionuclide uptake. Uptake, efflux, and subcellular location of the NIS radiotracer [
Identifiants
pubmed: 34948266
pii: ijms222413466
doi: 10.3390/ijms222413466
pmc: PMC8703725
pii:
doi:
Substances chimiques
Iodine Radioisotopes
0
Radiopharmaceuticals
0
Symporters
0
Technetium-99
0
sodium-iodide symporter
4XE5NDT4K1
Technetium
7440-26-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Academy of Medical Sciences
ID : SBF001\1019
Pays : United Kingdom
Organisme : Engineering and Physical Sciences Research Council
ID : EP/L015226/1
Organisme : Medical Research Council
ID : MR/N013700/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Wellcome Trust
ID : WT 203148/Z/16/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C48390/A21153
Pays : United Kingdom
Organisme : Engineering and Physical Sciences Research Council
ID : EP/S032789/1
Références
Int J Radiat Biol. 2016 Nov;92(11):698-706
pubmed: 27117205
Molecules. 2021 Jan 15;26(2):
pubmed: 33467760
Pharmaceutics. 2021 Jun 29;13(7):
pubmed: 34209637
Mol Ther. 2020 Oct 7;28(10):2271-2285
pubmed: 32645298
Front Med (Lausanne). 2015 Mar 17;2:12
pubmed: 25853132
Clin Cancer Res. 2020 Jun 15;26(12):2871-2881
pubmed: 32066626
Nucl Med Biol. 2021 Jul-Aug;98-99:18-29
pubmed: 33964707
EJNMMI Radiopharm Chem. 2019 Oct 11;4(1):27
pubmed: 31659527
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3365-3377
pubmed: 33912987
Nucl Med Biol. 2021 Mar-Apr;94-95:1-19
pubmed: 33461040
Endocr Rev. 2014 Feb;35(1):106-49
pubmed: 24311738
J Nucl Med. 2014 Sep;55(9):1557-64
pubmed: 25012457
EJNMMI Res. 2020 Jul 13;10(1):79
pubmed: 32661612
Eur J Nucl Med Mol Imaging. 2007 May;34(5):638-650
pubmed: 17160413
Med Phys. 2006 Sep;33(9):3260-9
pubmed: 17022220
J Vis Exp. 2018 Mar 13;(133):
pubmed: 29608157
Biomed Microdevices. 2020 Apr 25;22(2):31
pubmed: 32335724
Int J Radiat Biol. 2004 Nov-Dec;80(11-12):875-80
pubmed: 15764396
Mol Ther Methods Clin Dev. 2020 Dec 10;20:324-336
pubmed: 33511246
EJNMMI Res. 2021 Jul 5;11(1):63
pubmed: 34224019
Int J Radiat Biol. 2010 Apr;86(4):261-70
pubmed: 20353336
Nuklearmedizin. 2010;49(4):154-60
pubmed: 20490428
Med Phys. 2014 Jun;41(6):062503
pubmed: 24877837
Nucl Med Biol. 2017 Mar;46:12-18
pubmed: 27915165
Int J Radiat Biol. 2012 Dec;88(12):991-7
pubmed: 22967084
Nuklearmedizin. 2012;51(5):170-8
pubmed: 23037134